# Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

> **NCT01349114** · PHASE4 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 21 (actual)

## Conditions studied

- Diabetes
- Pre-hypertension
- Hypertension

## Interventions

- **DRUG:** aliskiren 300 mg once daily
- **DRUG:** Placebo/sugar pill

## Key facts

- **NCT ID:** NCT01349114
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Sponsor requested termination.
- **Last updated:** 2017-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349114, "Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01349114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*